Fig. 3: Logarithmic regression analysis for treatment rate per 10 million inhabitants by gross national income (GNI) per capita in USD in 46 countries with a population greater than 2 million in 2022. | Bone Marrow Transplantation

Fig. 3: Logarithmic regression analysis for treatment rate per 10 million inhabitants by gross national income (GNI) per capita in USD in 46 countries with a population greater than 2 million in 2022.

From: Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT

Fig. 3Fig. 3

a Allogeneic HCT (all transplants). b Autologous HCT (all transplants). c CAR-T treatments (1st transplant). d HLA identical sibling HCT (all transplants). e Unrelated HCT (all transplants). f Haploidentical family HCT (all transplants). g Cord blood HCT (all transplants). h Acute myeloid leukemia in 1st complete remission (1st transplant). i Myelodysplastic syndrome (1st transplant). j Myeloproliferative neoplasm HCT (1st transplant). k Bone marrow failure HCT (1st transplant). l Unrelated donor HCT rate by availability of unrelated donors within WMDA registries.

Back to article page